2 days ago
5
Attiya Zainib
Mon, May 18, 2026 astatine 7:32 AM CDT 3 min read
Latitude Investment Management, an concern absorption firm, released its fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The missive emphasizes a long-term, fundamentals-driven concern philosophy, arguing that portion banal prices tin beryllium volatile successful the abbreviated run, they yet travel underlying net growth—illustrated done the “dog and owner” analogy. The portfolio delivered beardown results successful 2025, with net increasing implicit 15% and returns of 21%, mostly driven by accordant cardinal maturation alternatively than valuation changes. The manager highlights a diversified portfolio of high-quality, cash-generative companies with coagulated marketplace positions, debased concern needs, and charismatic shareholder returns done dividends and buybacks. The missive notes selective portfolio shifts toward much defensive, attractively valued names portion maintaining double-digit maturation potential. Looking ahead, the outlook remains positive, with expectations for continued net growth, improving opportunities from marketplace dispersion, and charismatic valuations providing a borderline of information contempt constricted vulnerability to crowded themes similar AI. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2025.
In its fourth-quarter 2025 capitalist letter, Latitude Investment Management highlighted stocks similar Royalty Pharma (NASDAQ:RPRX). Royalty Pharma (NASDAQ:RPRX) is simply a pharmaceutical institution that acquires and manages royalty interests successful innovative biopharma products. The one-month instrumentality of Royalty Pharma (NASDAQ:RPRX) was 7.20% portion its shares traded betwixt $32.15 and $53.47 implicit the past 52 weeks. On May 15, 2026, Royalty Pharma (NASDAQ:RPRX) banal closed astatine astir $52.85 per share, with a marketplace capitalization of astir $30.44 billion.
Latitude Investment Management stated the pursuing regarding Royalty Pharma (NASDAQ:RPRX) in its Q4 2025 capitalist letter:
"When sectors are hot, superior flows successful with abandon, and the other is intelligibly existent too. Funding for biotech and pharmaceutical companies, which ballooned successful the years of abundant inexpensive capital, has since collapsed. Royalty Pharma (NASDAQ:RPRX) is filling the gap, and returns connected superior are rising arsenic a result. The institution has a 40-50% marketplace stock of each pharma royalties6 and remains ascendant today, contempt attempts astatine contention from ample backstage equity firms similar Blackstone. The accrued costs to bring a cause to market, and the lack of a credible alternate successful equity and enslaved markets, mean that royalties go an progressively charismatic mode of backing research. Barriers to introduction are besides high: relationships with pharma companies are built implicit decades, databases of palmy trials and probe necessitate clip to accumulate, and royalty holding periods are a batch longer than the lifespan of the mean backstage equity fund, making them a little assertive competitor. The institution has shown large quality successful diversifying its portfolio astatine coagulated double-digit returns and we were capable to get the shares astatine a highly charismatic introduction point."
.png)
English (CA) · 
English (US) · 
Spanish (MX) ·